Hikma Pharmaceuticals (LON:HIK)‘s stock had its “underperform” rating reiterated by research analysts at Jefferies Group in a report released on Wednesday. They presently have a GBX 895 ($12.14) target price on the stock. Jefferies Group’s price objective indicates a potential downside of 10.68% from the company’s previous close.

A number of other brokerages have also commented on HIK. JPMorgan Chase & Co. cut their price objective on shares of Hikma Pharmaceuticals from GBX 1,500 ($20.34) to GBX 1,250 ($16.95) and set a “neutral” rating on the stock in a research report on Friday, October 6th. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.85) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, October 31st. Numis Securities reissued a “buy” rating and issued a GBX 1,300 ($17.63) price objective on shares of Hikma Pharmaceuticals in a research report on Wednesday, December 20th. Morgan Stanley reissued an “equal weight” rating and issued a GBX 1,100 ($14.92) price objective on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. Finally, cut their price objective on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.37) to GBX 865 ($11.73) and set a “reduce” rating on the stock in a research report on Friday, November 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of GBX 1,171 ($15.88).

Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,002 ($13.59) on Wednesday. Hikma Pharmaceuticals has a one year low of GBX 906.50 ($12.29) and a one year high of GBX 2,346 ($31.81). The firm has a market cap of $2,410.00 and a P/E ratio of 2,004.00.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/17/jefferies-group-reaffirms-underperform-rating-for-hikma-pharmaceuticals-hik.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.